Cat. No. 3765
Alternative Names: PNU 100766, U 100766
Chemical Name: N-[[(5S)-3-[3-Fluoro-4-(4-morpholin
Biological ActivityOxazolidinone antibiotic. Inhibits bacterial protein synthesis prior to chain initiation. Displays potent antibacterial activity against a variety of multidrug-resistant gram-positive microbes in vitro and in vivo.
Licensing InformationSold for research purposes under agreement from Pfizer Inc.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Brickner et al (2008) Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections. J.Med.Chem. 51 1981. PMID: 18338841.
Brickner et al (1996) Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multi-drug-resistant gram-positive bacterial infections. J.Med.Chem. 39 673. PMID: 8576909.
Ford et al (1996) In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob.Agents Chemother. 40 1508. PMID: 8726028.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Linezolid from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Linezolid, supplier, PNU100766, U100766, antibacterial, antibiotics, gram-positive, bacteria, protein, synthesis, inhibitors, inhibits, Pfizer, Tocris Bioscience, DNA, RNA and Protein Synthesis Inhibitor products
Find multiple products by catalog number
New Products in this Area
PCNA inhibitorPladienolide B
mRNA splicing inhibitor; antitumorLin28 1632
RNA binding protein Lin28 inhibitor; promotes mESC differentiation; also bromodomain inhibitor
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.